Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...

Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Sanofi wins ‘Top GCC of 2025’ and ‘GCC Country Leader of the Year’ at Zyoin Group workplace summit and awards 2025: Our Bureau, Bengaluru Monday, July 14, 2025, 15:30 Hrs ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Five acquisitions in 2025—including Cargo and Allakos—have put Concentra Biosciences in the spotlight. Learn what’s behind ...

Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...

Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...